NCT07439653

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 155 (estimated)
• Sponsor: TORL Biotherapeutics, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Conditions

• Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	TORL-5-700	Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks
DRUG	TORL-5-700 at MTD/RP2D	Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks
DRUG	TORL-5-700 at MTD/RP2D in combination with another agent	Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent

Timeline

• Start date: 2026-01-30
• Primary completion: 2029-03-31
• Completion: 2029-09-30
• First posted: 2026-02-27
• Last updated: 2026-02-27

Regulatory

• FDA-regulated drug study